Trial Profile
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Proof of concept; Therapeutic Use
- Sponsors Rhythm
- 27 Mar 2023 According to a Rhythm media release, Interview based research on setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food published in peer-reviewed journal Advances in Therapy. Company also announced publication of health state utilities study in hyperphagia.
- 24 Mar 2023 Results of Patients with BBS or their caregivers who participated in NCT03013543 and NCT03746522; assessing impact of hyperphagia on the lives of patients , published in the Advances in Therapy
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.